(Q33776160)

29 July 2017

1 reference

title

Therapeutic vaccines in HIV.1 infection (English)

1 reference

29 July 2017

1 reference

Gotch F

1

1 reference

PubMed ID

10566150

29 July 2017

Hardy G

series ordinal

2

1 reference

PubMed ID

10566150

29 July 2017

Imami N

series ordinal

3

1 reference

29 July 2017

1 August 1999

1 reference

29 July 2017

Immunological Reviews

1 reference

29 July 2017

170

1 reference

29 July 2017

173-182

1 reference

Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor

29 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Adherence and effectiveness of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Interleukin-2 as therapy for HIV disease. Dinitrochlorobenzene Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Gene vaccination with naked plasmid DNA: mechanism of CTL priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Nucleic acid vaccines: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4+ T Cell Turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

A role for mucosal immunity in resistance to HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Active Immunization of Patients with HIV Infection: A Study of the Effect of VaxSyn, a Recombinant HIV Envelope Subunit Vaccine, on Progression of Immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Prospects for the control of AIDS by immunizing seropositive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

HIV infection: how effective is drug combination treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Access to treatment for HIV in developing countries; statement from international seminar on access to treatment for HIV in developing countries, London, June 5 and 6, 1998

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Interleukin-2 as therapy for HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Induction of specific T-cell responses in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Fusion potential for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01337.X

10.1111/J.1600-065X.1999.TB01337.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10566150